ResearcherJohns Hopkins UniversityActive in the last 2 years

Jin He

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5124919273. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 26

Papers, trials and grants by year

2026: 2 papers

Papers 2

Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally advanced pancreatic cancer: a propensity s… Co-author DOI 10.1016/j.gassur.2026.102358 ↗
Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.gassur.2026.102359 ↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

William Reece Burns · 2 shared papers, 2026 · strength 0.48
- Paper Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.gassur.2026.102359 ↗
- Paper Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally ad… DOI 10.1016/j.gassur.2026.102358 ↗
Eric Scott Christenson · 1 shared paper, 2026 · strength 0.25
- Paper Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.gassur.2026.102359 ↗
Dung Thi Le · 1 shared paper, 2026 · strength 0.25
- Paper Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.gassur.2026.102359 ↗
Christopher R. Shubert · 1 shared paper, 2026 · strength 0.25
- Paper Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.gassur.2026.102359 ↗
Sagar D. Patel · 1 shared paper, 2026 · strength 0.25
- Paper Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.gassur.2026.102359 ↗
Kelly J. Lafaro · 1 shared paper, 2026 · strength 0.25
- Paper Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.gassur.2026.102359 ↗
Richard Andrew Burkhart · 1 shared paper, 2026 · strength 0.25
- Paper Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.gassur.2026.102359 ↗
Matthew Z. Guo · 1 shared paper, 2026 · strength 0.25
- Paper Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.gassur.2026.102359 ↗
Elizabeth M. Jaffee · 1 shared paper, 2026 · strength 0.25
- Paper Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.gassur.2026.102359 ↗
Michael Jon Pishvaian · 1 shared paper, 2026 · strength 0.25
- Paper Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.gassur.2026.102359 ↗
Katherine M. Bever · 1 shared paper, 2026 · strength 0.25
- Paper Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.gassur.2026.102359 ↗
Daniel A. Laheru · 1 shared paper, 2026 · strength 0.25
- Paper Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.gassur.2026.102359 ↗
Timothy R. Donahue · 1 shared paper, 2026 · strength 0.23
- Paper Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally ad… DOI 10.1016/j.gassur.2026.102358 ↗
Zev A. Wainberg · 1 shared paper, 2026 · strength 0.23
- Paper Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally ad… DOI 10.1016/j.gassur.2026.102358 ↗
Theodore Sunki Hong · 1 shared paper, 2026 · strength 0.23
- Paper Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally ad… DOI 10.1016/j.gassur.2026.102358 ↗
Carlos Fernández-del Castillo · 1 shared paper, 2026 · strength 0.23
- Paper Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally ad… DOI 10.1016/j.gassur.2026.102358 ↗
Shimpei Maeda · 1 shared paper, 2026 · strength 0.23
- Paper Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally ad… DOI 10.1016/j.gassur.2026.102358 ↗
Takayuki Shimizu · 1 shared paper, 2026 · strength 0.23
- Paper Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally ad… DOI 10.1016/j.gassur.2026.102358 ↗
Jason M. Link · 1 shared paper, 2026 · strength 0.23
- Paper Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally ad… DOI 10.1016/j.gassur.2026.102358 ↗
Mark D. Girgis · 1 shared paper, 2026 · strength 0.23
- Paper Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally ad… DOI 10.1016/j.gassur.2026.102358 ↗
Motaz Qadan · 1 shared paper, 2026 · strength 0.23
- Paper Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally ad… DOI 10.1016/j.gassur.2026.102358 ↗
Jonathan C. King · 1 shared paper, 2026 · strength 0.23
- Paper Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally ad… DOI 10.1016/j.gassur.2026.102358 ↗
Jennifer Yon-Li Wo · 1 shared paper, 2026 · strength 0.23
- Paper Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally ad… DOI 10.1016/j.gassur.2026.102358 ↗
Keith D. Lillemoe · 1 shared paper, 2026 · strength 0.23
- Paper Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally ad… DOI 10.1016/j.gassur.2026.102358 ↗
Oscar Joe Hines · 1 shared paper, 2026 · strength 0.23
- Paper Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally ad… DOI 10.1016/j.gassur.2026.102358 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.